Literature DB >> 16755382

In vivo detection of iron and neuromelanin by transcranial sonography--a new approach for early detection of substantia nigra damage.

D Berg1.   

Abstract

In more than 90% of patients with idiopathic Parkinson's disease (PD) hyperechogenicity of the substantia nigra (SN) can be found by transcranial sonography (TCS) as a typical, stable sign. Animal experiments provided first evidence that SN hyperechogenicity may be associated with increased tissue iron levels. Two consecutive studies revealed the same association in human brain. Postmortem brains of 60 subjects without clinical signs for Parkinson's disease during life time at different ages were scanned by ultrasound with planimetric measurement of the echogenic area of the SN. Afterwards the SN was dissected and used for histological examination and determination of iron content in all brains as well as ferritin and neuromelanin content in 40 brains. A significant positive correlation was found between the echogenic area of the SN and the concentration of iron, H- and L-ferritins. A multivariate analysis performed considering the iron content showed a significant negative correlation between echogenicity and neuromelanin content of the SN. Iron staining confirmed the biochemical findings. In PD a typical loss of neuromelanin and increase of iron is observed in this brain area. However, it is not clear yet, whether iron accumulation is a primary cause or a secondary phenomenon in the disease process. Screening of genes involved in brain iron metabolism showed a significant association of some sequence variations of the ceruloplasmin gene with PD. Others were associated with the ultrasound marker for increased iron levels in both PD patients and control subjects. As SN hyperechogenicity is typical for PD or subjects with a preclinical impairment of the nigrostriatal system, these findings indicate that TCS enables the detection of increased iron and decreased neuromelanin levels at the SN, even before the clinical manifestation of PD.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16755382     DOI: 10.1007/s00702-005-0447-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  11 in total

1.  Functional relevance of ceruloplasmin mutations in Parkinson's disease.

Authors:  Helmine Hochstrasser; Jürgen Tomiuk; Uwe Walter; Stefanie Behnke; Jörg Spiegel; Rejko Krüger; Georg Becker; Olaf Riess; Daniela Berg
Journal:  FASEB J       Date:  2005-09-08       Impact factor: 5.191

Review 2.  Imaging iron stores in the brain using magnetic resonance imaging.

Authors:  E Mark Haacke; Norman Y C Cheng; Michael J House; Qiang Liu; Jaladhar Neelavalli; Robert J Ogg; Asadullah Khan; Muhammad Ayaz; Wolff Kirsch; Andre Obenaus
Journal:  Magn Reson Imaging       Date:  2005-01       Impact factor: 2.546

3.  Vulnerability of the nigrostriatal system as detected by transcranial ultrasound.

Authors:  D Berg; G Becker; B Zeiler; O Tucha; E Hofmann; M Preier; P Benz; W Jost; K Reiners; K W Lange
Journal:  Neurology       Date:  1999-09-22       Impact factor: 9.910

4.  Echogenicity of the substantia nigra in Parkinson's disease and its relation to clinical findings.

Authors:  D Berg; C Siefker; G Becker
Journal:  J Neurol       Date:  2001-08       Impact factor: 4.849

5.  Iron accumulation in the substantia nigra in rats visualized by ultrasound.

Authors:  D Berg; C Grote; W D Rausch; M Mäurer; W Wesemann; P Riederer; G Becker
Journal:  Ultrasound Med Biol       Date:  1999-07       Impact factor: 2.998

6.  Ceruloplasmin gene variations and substantia nigra hyperechogenicity in Parkinson disease.

Authors:  H Hochstrasser; P Bauer; U Walter; S Behnke; J Spiegel; I Csoti; B Zeiler; A Bornemann; J Pahnke; G Becker; O Riess; D Berg
Journal:  Neurology       Date:  2004-11-23       Impact factor: 9.910

7.  In vivo detection of iron and neuromelanin by transcranial sonography: a new approach for early detection of substantia nigra damage.

Authors:  Luigi Zecca; Daniela Berg; Thomas Arzberger; Petra Ruprecht; Wolf D Rausch; Massimo Musicco; Davide Tampellini; Peter Riederer; Manfred Gerlach; Georg Becker
Journal:  Mov Disord       Date:  2005-10       Impact factor: 10.338

8.  Five-year follow-up study of hyperechogenicity of the substantia nigra in Parkinson's disease.

Authors:  Daniela Berg; Berthold Merz; Karlheinz Reiners; Markus Naumann; Georg Becker
Journal:  Mov Disord       Date:  2005-03       Impact factor: 10.338

9.  Echogenicity of the substantia nigra: association with increased iron content and marker for susceptibility to nigrostriatal injury.

Authors:  Daniela Berg; Wolfgang Roggendorf; Ute Schröder; Rüdiger Klein; Thomas Tatschner; Peter Benz; Oliver Tucha; Michael Preier; Klaus W Lange; Karlheinz Reiners; Manfred Gerlach; Georg Becker
Journal:  Arch Neurol       Date:  2002-06

10.  Degeneration of substantia nigra in chronic Parkinson's disease visualized by transcranial color-coded real-time sonography.

Authors:  G Becker; J Seufert; U Bogdahn; H Reichmann; K Reiners
Journal:  Neurology       Date:  1995-01       Impact factor: 9.910

View more
  15 in total

Review 1.  Substantia nigra hyperechogenicity is a risk marker of Parkinson's disease: yes.

Authors:  Daniela Berg
Journal:  J Neural Transm (Vienna)       Date:  2011-01-05       Impact factor: 3.575

2.  Detection of MPTP-induced substantia nigra hyperechogenicity in Rhesus monkeys by transcranial ultrasound.

Authors:  Thyagarajan Subramanian; Christopher A Lieu; Kumaraswamy Guttalu; Daniela Berg
Journal:  Ultrasound Med Biol       Date:  2010-03-07       Impact factor: 2.998

Review 3.  Mitochondrial iron metabolism and its role in neurodegeneration.

Authors:  Maxx P Horowitz; J Timothy Greenamyre
Journal:  J Alzheimers Dis       Date:  2010       Impact factor: 4.472

4.  Multimodal imaging of a patient with RAB39B mutation.

Authors:  Laurane Mackels; Martin Moïse; Frédérique Depierreux
Journal:  Neuroradiology       Date:  2022-01-27       Impact factor: 2.804

Review 5.  Iron accumulation in Parkinson's disease.

Authors:  Hideki Mochizuki; Toru Yasuda
Journal:  J Neural Transm (Vienna)       Date:  2012-10-16       Impact factor: 3.575

Review 6.  Brain Iron Metabolism Dysfunction in Parkinson's Disease.

Authors:  Hong Jiang; Jun Wang; Jack Rogers; Junxia Xie
Journal:  Mol Neurobiol       Date:  2016-04-02       Impact factor: 5.590

7.  Quantitative susceptibility mapping by inversion of a perturbation field model: correlation with brain iron in normal aging.

Authors:  Clare B Poynton; Mark Jenkinson; Elfar Adalsteinsson; Edith V Sullivan; Adolf Pfefferbaum; William Wells
Journal:  IEEE Trans Med Imaging       Date:  2014-09-16       Impact factor: 10.048

Review 8.  Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples.

Authors:  Douglas B Kell
Journal:  Arch Toxicol       Date:  2010-08-17       Impact factor: 5.153

Review 9.  Challenges and Opportunities of Deferoxamine Delivery for Treatment of Alzheimer's Disease, Parkinson's Disease, and Intracerebral Hemorrhage.

Authors:  Amy Corbin Farr; May P Xiong
Journal:  Mol Pharm       Date:  2020-10-09       Impact factor: 4.939

Review 10.  Nigral iron elevation is an invariable feature of Parkinson's disease and is a sufficient cause of neurodegeneration.

Authors:  Scott Ayton; Peng Lei
Journal:  Biomed Res Int       Date:  2014-01-16       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.